Collaboration provides Sirtex the right to co-promote OncoSec lead product candidate TAVO™ for the treatment of advanced melanoma
The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO™ and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec.
TAVO™ is DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. TAVO™ is administered directly into the tumor using OncoSec’s proprietary EP gene delivery system, which employs a series of momentary energy pulses. Those pulses are designed to increase the permeability of the cell membrane and facilitate uptake of IL-12 coded DNA into the tumor cells. TAVO™ is a potential treatment for multiple cancer indications as a monotherapy or in combination with leading checkpoint inhibitors. Currently, TAVO™ is in its pivotal clinical trial for advanced melanoma (KEYNOTE-695).
"We are thrilled to advance our partnership with OncoSec as the clinical development of TAVO™ progresses," said Kevin R. Smith, Chief Executive Officer of Sirtex. "OncoSec is committed to bringing much-needed treatment options to patients with cancer, and we are excited to continue supporting them in that journey.”\"
This agreement further extends the existing collaboration between Sirtex and OncoSec. Last year, Sirtex acquired an equity stake in OncoSec and entered an arrangement to assist OncoSec with pre-marketing activities for TAVO™ and its Visceral Lesion Applicator (VLA) product in exchange for a low single-digit royalty. More details of the transaction documents can be found in OncoSec’s filings with the U.S. Securities and Exchange Commission.
"Our collaboration with Sirtex is a natural fit given our common mission to deliver more effective therapies to patients," said Daniel J. O’Connor, CEO of OncoSec. "We are thankful for Sirtex’s continued support as we advance our TAVO™ clinical program and diligently work to bring this treatment option to market."
Sirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. For more information, visit www.sirtex.com. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.
You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.
Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.
Click 'Continue' to proceed to the third-party Web site.
You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.
Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.
The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region.
Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.
Click 'Continue' to proceed to the other Sirtex region Web site.
By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.
Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.
Click here to view our Technical Bulletin.